[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1222853A1 - 氘化苯並喹啉衍生物作為囊泡單胺轉運 的抑制劑 - Google Patents

氘化苯並喹啉衍生物作為囊泡單胺轉運 的抑制劑

Info

Publication number
HK1222853A1
HK1222853A1 HK16111056.0A HK16111056A HK1222853A1 HK 1222853 A1 HK1222853 A1 HK 1222853A1 HK 16111056 A HK16111056 A HK 16111056A HK 1222853 A1 HK1222853 A1 HK 1222853A1
Authority
HK
Hong Kong
Prior art keywords
deuterated
inhibitors
monoamine transporter
vesicular monoamine
benzoquinolizine
Prior art date
Application number
HK16111056.0A
Other languages
English (en)
Inventor
G Gant Thomas
Shahbaz Manoucherhr
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1222853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of HK1222853A1 publication Critical patent/HK1222853A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16111056.0A 2008-09-18 2016-09-21 氘化苯並喹啉衍生物作為囊泡單胺轉運 的抑制劑 HK1222853A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9789608P 2008-09-18 2008-09-18

Publications (1)

Publication Number Publication Date
HK1222853A1 true HK1222853A1 (zh) 2017-07-14

Family

ID=42107127

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13114111.0A HK1186728A1 (zh) 2008-09-18 2013-12-20 重氫代苯並喹啉衍生物作為囊泡單胺轉運體 的抑制劑
HK16111056.0A HK1222853A1 (zh) 2008-09-18 2016-09-21 氘化苯並喹啉衍生物作為囊泡單胺轉運 的抑制劑
HK19100241.6A HK1257880A1 (zh) 2008-09-18 2019-01-08 氘化的苯並喹啉衍生物作為纈氨酸單胺轉運蛋白2的抑制劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13114111.0A HK1186728A1 (zh) 2008-09-18 2013-12-20 重氫代苯並喹啉衍生物作為囊泡單胺轉運體 的抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK19100241.6A HK1257880A1 (zh) 2008-09-18 2019-01-08 氘化的苯並喹啉衍生物作為纈氨酸單胺轉運蛋白2的抑制劑

Country Status (20)

Country Link
US (15) US8524733B2 (zh)
EP (4) EP3345905B1 (zh)
JP (3) JP5616345B2 (zh)
CN (2) CN102186848B (zh)
AU (1) AU2009303758B8 (zh)
BR (1) BRPI0913457B8 (zh)
CA (2) CA2972242A1 (zh)
CY (1) CY1120060T1 (zh)
DK (2) DK3061760T3 (zh)
ES (4) ES2652289T3 (zh)
HK (3) HK1186728A1 (zh)
HR (1) HRP20180239T1 (zh)
HU (1) HUE038158T2 (zh)
LT (1) LT3061760T (zh)
NO (1) NO3061760T3 (zh)
NZ (1) NZ591615A (zh)
PL (1) PL3061760T3 (zh)
PT (1) PT3061760T (zh)
SI (1) SI3061760T1 (zh)
WO (1) WO2010044981A2 (zh)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3061760T3 (zh) 2008-09-18 2018-04-07
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
BR112013007496A2 (pt) 2010-08-27 2019-09-24 Sienna Labs Inc composições e métodos para termo modulação específica
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CA3124804C (en) * 2012-09-18 2023-08-22 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN108480620A (zh) 2012-10-11 2018-09-04 纳诺康波西克斯公司 银纳米片组合物及方法
BR112015017878A2 (pt) 2013-01-31 2017-07-11 Auspex Pharmaceuticals Inc composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2
US20160207917A1 (en) * 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
EP3071565A4 (en) * 2013-11-22 2017-08-02 Auspex Pharmaceuticals, Inc. Methods of treating abnormal muscular activity
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20150152099A1 (en) * 2013-12-03 2015-06-04 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP3398602A1 (en) * 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016010071A (es) * 2014-02-07 2017-04-27 Neurocrine Biosciences Inc Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
CA2938244A1 (en) 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Novel pharmaceutical formulations
PT3936130T (pt) 2014-05-06 2024-04-17 Neurocrine Biosciences Inc Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CN114788824A (zh) * 2015-03-06 2022-07-26 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
WO2016154017A1 (en) * 2015-03-20 2016-09-29 Sienna Biopharmaceuticals, Inc. Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
PT3394057T (pt) 2015-12-23 2022-04-21 Neurocrine Biosciences Inc Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
WO2017182916A1 (en) 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
WO2017221169A1 (en) 2016-06-24 2017-12-28 Lupin Limited Premixes of deutetrabenazine
CN107936008B (zh) * 2016-10-13 2022-06-14 泰州华元医药科技有限公司 氘代化合物及其医药用途
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
CN110740731A (zh) 2017-01-27 2020-01-31 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CA3056612A1 (en) 2017-03-15 2018-09-20 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10786495B2 (en) * 2017-10-10 2020-09-29 The Regents Of The University Of California Vesicular monoamine transporter 2 inhibitors for treating stuttering
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
WO2019130252A2 (en) * 2017-12-29 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing deutetrabenazine
CN111655243A (zh) 2018-01-29 2020-09-11 乔纳森·萨克纳-伯恩斯坦 在人类神经系统疾病中调节多巴胺的方法
WO2019150387A1 (en) * 2018-02-01 2019-08-08 Alaparthi Lakshmi Prasad A novel process for preparation of deutetrabenazine
WO2019166962A1 (en) 2018-03-01 2019-09-06 Mylan Laboratories Ltd Deutetrabenazine polymorphs and methods for their preparation
ES2968827T3 (es) * 2018-04-25 2024-05-14 Shinkei Therapeutics Inc Dispositivo de administración transdérmica de tetrabenazina
US10632107B2 (en) 2018-05-14 2020-04-28 Apotex Inc. Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2021528386A (ja) 2018-06-14 2021-10-21 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法
CN108794337A (zh) * 2018-07-10 2018-11-13 上海华堇生物技术有限责任公司 一种3,4-二羟基-β-硝基苯乙烯的新制备方法
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20210078487A (ko) 2018-10-18 2021-06-28 온코펩타이드즈 아베 중수소 함유 화합물
SG11202106344SA (en) * 2018-12-13 2021-07-29 Auspex Pharmaceuticals Inc Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
CN113438990B (zh) 2019-02-22 2023-06-23 株式会社Ihi 推力箔片轴承、推力箔片轴承的底板的制造方法
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
HUE065723T2 (hu) 2020-06-10 2024-06-28 Auspex Pharmaceuticals Inc Deutetrabenazint tartalmazó ozmotikus adagolási formák és eljárás ezek alkalmazására
CN116322657A (zh) 2020-09-17 2023-06-23 奥斯佩克斯医药公司 包括氘代丁苯那嗪的多颗粒剂型
CN116456970A (zh) 2020-10-12 2023-07-18 奥斯佩克斯医药公司 包括氘代丁苯那嗪的胃滞留剂型
BR112023016273A2 (pt) 2021-03-22 2023-10-03 Neurocrine Biosciences Inc Inibidores de vmat2 e métodos de uso
WO2023278987A1 (en) 2021-06-30 2023-01-05 Neurocrine Biosciences, Inc. Valbenazine for use in the add-on treatment of schizophrenia
KR20240055160A (ko) 2021-09-17 2024-04-26 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진을 포함하는 다중미립자 제형
MX2024010544A (es) 2022-03-07 2024-09-06 Neurocrine Biosciences Inc Valbenazina, un inhibidor de la isoforma 2 del transportador de monoamina vesicular humano (vmat2), como base libre, sal de tosilato o de ditosilato para usarse en el tratamiento de corea asociada a la enfermedad de huntington.
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
DE1253271B (de) * 1961-03-28 1967-11-02 Mta Verfahren zur Herstellung von 2-Oxo-1, 2, 3, 4, 6, 7-hexahydro-11bH-benzo[a]chinolizinen
US4316897A (en) * 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004292966A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
WO2006078846A1 (en) 2005-01-19 2006-07-27 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2012833B1 (en) 2006-05-02 2014-10-29 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotrabenazine derivatives and their use as imaging agents
CN101553487B (zh) 2006-11-08 2012-06-13 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
EP2078026B1 (en) 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
WO2008112278A2 (en) 2007-03-12 2008-09-18 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
US7897768B2 (en) * 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
DK2173344T3 (en) * 2007-06-29 2016-07-25 Clarencew Pty Ltd TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEURO PSYCHIATRIC DISORDERS USING ocular administration
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
NO3061760T3 (zh) * 2008-09-18 2018-04-07
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011106248A2 (en) 2010-02-24 2011-09-01 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂

Also Published As

Publication number Publication date
CN104311552A (zh) 2015-01-28
US20160367548A1 (en) 2016-12-22
ES2896678T3 (es) 2022-02-25
CN102186848A (zh) 2011-09-14
HRP20180239T1 (hr) 2018-05-18
BRPI0913457B8 (pt) 2021-08-31
US20190375746A1 (en) 2019-12-12
WO2010044981A2 (en) 2010-04-22
EP3345905B1 (en) 2021-09-01
EP2610254A1 (en) 2013-07-03
JP2016172782A (ja) 2016-09-29
CY1120060T1 (el) 2018-12-12
HK1257880A1 (zh) 2019-11-01
BRPI0913457B1 (pt) 2021-07-20
ES2563820T3 (es) 2016-03-16
NZ591615A (en) 2012-07-27
US20100130480A1 (en) 2010-05-27
AU2009303758A1 (en) 2010-04-22
JP5616345B2 (ja) 2014-10-29
PT3061760T (pt) 2018-01-04
US20140206713A1 (en) 2014-07-24
HUE038158T2 (hu) 2018-09-28
HK1186728A1 (zh) 2014-03-21
AU2009303758A8 (en) 2015-02-19
EP2326643A2 (en) 2011-06-01
JP2012503010A (ja) 2012-02-02
BRPI0913457A2 (pt) 2020-06-09
NO3061760T3 (zh) 2018-04-07
EP2326643B1 (en) 2013-05-29
US20160220558A1 (en) 2016-08-04
AU2009303758B2 (en) 2014-10-23
JP2015007124A (ja) 2015-01-15
JP5970037B2 (ja) 2016-08-17
SI3061760T1 (en) 2018-04-30
US20150328207A1 (en) 2015-11-19
LT3061760T (lt) 2018-02-26
EP3061760A1 (en) 2016-08-31
US8524733B2 (en) 2013-09-03
US20150080427A1 (en) 2015-03-19
CA2972242A1 (en) 2010-04-22
PL3061760T3 (pl) 2018-07-31
US20140350044A1 (en) 2014-11-27
US20160158220A1 (en) 2016-06-09
ES2652289T3 (es) 2018-02-01
US20140206712A1 (en) 2014-07-24
CA2736409C (en) 2017-07-11
WO2010044981A3 (en) 2010-06-17
EP2326643A4 (en) 2012-03-21
ES2425623T3 (es) 2013-10-16
DK2326643T3 (da) 2013-08-05
EP2610254B1 (en) 2015-11-25
US20200347048A1 (en) 2020-11-05
DK3061760T3 (en) 2018-02-05
US20130296360A1 (en) 2013-11-07
EP3061760B1 (en) 2017-11-08
CA2736409A1 (en) 2010-04-22
JP6138322B2 (ja) 2017-05-31
EP3345905A1 (en) 2018-07-11
US20220267317A1 (en) 2022-08-25
US20170166562A1 (en) 2017-06-15
US20160375005A1 (en) 2016-12-29
CN102186848B (zh) 2014-11-12
AU2009303758B8 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
HK1257880A1 (zh) 氘化的苯並喹啉衍生物作為纈氨酸單胺轉運蛋白2的抑制劑
HRP20180662T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
HK1223272A1 (zh) 程序性壞死的小分子抑制劑
PL2178840T3 (pl) Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh
HK1139936A1 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
EP2297174A4 (en) EXCLUSIVE SYNTHESIS OF GALACTOSIDE INHIBITORS
ZA201005435B (en) Oxim derivatives as hsp90 inhibitors
HK1143367A1 (zh) 用作 抑制劑的喹唑啉-肟衍生物
IL210990A0 (en) Piperidine derivatives as jak3 inhibitors
ZA200904916B (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
HK1156306A1 (zh) 作為 -脯氨酰基- -羥化酶抑制劑的取代的二氫吡唑啉酮類化合物
EP2486039A4 (en) HSP90 INHIBITORS SUITABLE PURE DERIVATIVES
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
EP2488032A4 (en) PROSTAGLAND INTRANSPORTERMER AND ITS USE
GB0808286D0 (en) Inhibitors of HSP90
AP2009005039A0 (en) Mono-hydrochloric salts of an inhibitor of histonedeacetylase
ZA201000383B (en) Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors